Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06987513 · ClinicalTrials.gov registry record · Phase 2

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

A Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Altimmune.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
12
Study locations

NCT06987513 is a Phase 2 study of Alcohol Use Disorder (AUD) that is active but no longer recruiting, run by Altimmune. The registered enrollment target is 100 participants, below the 1,821-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06987513, a Phase 2 study of Alcohol Use Disorder (AUD), is active but no longer recruiting, sponsored by Altimmune.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
12
Study locations

Study Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Conditions Studied

Alcohol Use Disorder (AUD)

Interventions

  • OTHER Placebo
  • DRUG Pemvidutide

Study Locations (12)

Florida

  • Altimmune Clinical Study Site - Fort Myers
  • Altimmune Clinical Study Site - University Park

Virginia

  • Altimmune Clinical Study Site - Charlottesville
  • Altimmune Clinical Study Site - Richmond

California

  • Altimmune Clinical Study Site - Los Angeles

Colorado

  • Altimmune Clinical Study Site - Aurora

Connecticut

  • Altimmune Clinical Study Site - New Haven

Ohio

  • Altimmune Clinical Study Site - North Canton

Oklahoma

  • Altimmune Clinical Study Site - Tulsa

Pennsylvania

  • Altimmune Clinical Study Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-15
Est. Completion 2026-06
Phase Phase 2

Sponsor

Altimmune

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06987513

The ClinicalTrials.gov registry entry for NCT06987513 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,821-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (95% lower). The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06987513 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Florida, Virginia, California.

Frequently Asked Questions

What is clinical trial NCT06987513 about?

NCT06987513 is a clinical study titled "RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1...

What is the current status of trial NCT06987513?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-05-15. Estimated completion is 2026-06.

What conditions does trial NCT06987513 study?

This clinical trial studies the following conditions: Alcohol Use Disorder (AUD).

What interventions are being tested in trial NCT06987513?

The interventions under investigation include: Placebo (OTHER), Pemvidutide (DRUG).

Who is sponsoring clinical trial NCT06987513?

This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06987513 being conducted?

This trial has 12 study locations across California, Colorado, Connecticut, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Use Disorder (AUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alcohol Use Disorder (AUD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.